idoxuridine has been researched along with 1-(2-deoxy-beta-ribofuranosyl)-5-iodo-2-pyrimidinone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CN; Cheng, YC; Doong, SL | 1 |
| Cheng, YC; Kinsella, TJ; Kunugi, KA; Liu, SH; McCulloch, W; Vielhuber, KA | 1 |
| Collins, JM; Fitzsimmons, ME; Kinsella, TJ; Kunugi, KA; Potter, DM; Vielhuber, KA | 1 |
| Davis, TW; Kinsella, TJ; Kunugi, KA; Sands, H; Schupp, J; Vielhuber, KA | 1 |
| Balis, F; Barnett, J; Berry, SE; Davis, TW; Hwang, HS; Kinsella, TJ; Sands, H; Schupp, JE; Warren, K | 1 |
| Kinsella, TJ; Radivoyevitch, T; Schupp, JE; Seo, Y; Yan, T | 1 |
| Burback, B; Hong, S; Johnson, JP; Kinsella, MT; Kinsella, TJ; Tosca, PJ | 1 |
| Anderson, LW; Collins, JM; DiPetrillo, T; Hill, KD; Kinsella, T; Kunos, C; Rosati, K; Safran, H; Schumacher, A; Vatkevich, J; Wiersma, S | 1 |
1 trial(s) available for idoxuridine and 1-(2-deoxy-beta-ribofuranosyl)-5-iodo-2-pyrimidinone
| Article | Year |
|---|---|
Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Dose Fractionation, Radiation; Feasibility Studies; Female; Gastrointestinal Neoplasms; Humans; Idoxuridine; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prodrugs; Pyrimidine Nucleosides; Radiation-Sensitizing Agents; Treatment Outcome | 2019 |
7 other study(ies) available for idoxuridine and 1-(2-deoxy-beta-ribofuranosyl)-5-iodo-2-pyrimidinone
| Article | Year |
|---|---|
Conversion of 5-iodo-2-pyrimidinone-2'-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design.
Topics: Aldehyde Oxidase; Aldehyde Oxidoreductases; Animals; Drug Design; Humans; Idoxuridine; Kidney; Pyrimidine Nucleosides; Radiation-Sensitizing Agents; Rats; Spleen; Substrate Specificity; Tissue Extracts | 1992 |
An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
Topics: Administration, Oral; Animals; Colonic Neoplasms; DNA; Female; Humans; Idoxuridine; Liver; Liver Neoplasms; Mice; Neoplasm Transplantation; Pyrimidine Nucleosides; Tissue Distribution | 1994 |
Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Topics: Animals; DNA; Female; Humans; Idoxuridine; Mice; Mice, Nude; Neoplasms, Experimental; Prodrugs; Pyrimidine Nucleosides; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1998 |
Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Topics: Administration, Oral; Aldehyde Oxidase; Aldehyde Oxidoreductases; Animals; Body Weight; DNA; Drug Administration Schedule; Female; Humans; Idoxuridine; Liver Extracts; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Prodrugs; Pyrimidine Nucleosides; Radiation-Sensitizing Agents; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
Topics: Aldehyde Oxidoreductases; Animals; Bone Marrow; DNA; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Ferrets; Hematologic Tests; Idoxuridine; Liver; Macaca mulatta; Male; Prodrugs; Pyrimidine Nucleosides; Radiation-Sensitizing Agents; Stomach; Urine | 2000 |
Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
Topics: Administration, Oral; Animals; Area Under Curve; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Glioblastoma; Humans; Idoxuridine; Mice; Mice, Nude; Pyrimidine Nucleosides; Radiation-Sensitizing Agents; Time Factors; Xenograft Model Antitumor Assays | 2005 |
Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization.
Topics: Animals; Antimetabolites; Area Under Curve; Biological Availability; Blood Cell Count; Clinical Trials, Phase I as Topic; Female; Half-Life; Idoxuridine; Intestinal Absorption; Male; Pyrimidine Nucleosides; Radiation-Sensitizing Agents; Rats; Rats, Inbred F344 | 2008 |